<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Spevak, Aimee</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Mehran, Roxana</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">REGULATE-PCI Trial</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-04-24 09:14:01</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">12-13</style></pages><abstract><style  face="normal" font="default" size="100%">The REGULATE-PCI trial compared REG1, a novel factor IXa inhibitor system for patients undergoing percutaneous coronary intervention, with bivalirudin for safety and efficacy outcomes. After just under a year of data collection, an unexpected increase in severe allergic reaction to the REG1 system led to early termination of the trial.</style></abstract><number><style face="normal" font="default" size="100%">5</style></number><volume><style face="normal" font="default" size="100%">15</style></volume></record></records></xml>